Stem Cell Treatment for Early Systemic Sclerosis
Treatments studied
Part of Skin clinical trials.
This trial tests whether special cells from umbilical cord (UC-MSC) can help treat systemic sclerosis—a disease that causes skin and organ hardening. If you have early systemic sclerosis that hasn't improved enough with standard treatments, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with diffuse cutaneous systemic sclerosis (a widespread form affecting the skin) discovered within the last 5 years
- You must have already tried at least two standard treatments (like corticosteroids, immunosuppressants, or biologic drugs)
- Your skin thickness score must be moderate—not too mild and not too severe—as measured by doctors
- Your lung function must be reasonably preserved (at least 50% of normal lung capacity)
- You cannot have severe heart or kidney problems, or serious infections like HIV, hepatitis B or C
- You must be 18 to 65 years old and willing to use birth control for 6 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study uses special lab-grown stem cells to understand how systemic sclerosis (a disease that hardens skin and organs) develops and progresses. By studying cells from patients with different types of systemic sclerosis and healthy relatives, researchers hope to find new ways to treat or prevent the disease.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
This study tests a new cell therapy called CD19 CAR-T for patients with systemic sclerosis that hasn't improved with standard treatments. The therapy aims to help reduce skin tightening and other symptoms.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.